The diagnosis of idiopathic hyperammonemia (IH) is made in the presence of elevated serum ammonia, neurological deterioration of no other obvious aetiology, normal liver function tests and normal amino-acid levels, which rule out enzymatic deficiencies of the urea cycle. Pathological features include presence of Alzheimer type II astrocytes in brain and centrilobular microvesicular steatosis. An acquired deficiency of glutamine synthetase of unknown origin has been suggested as a possible mechanism.
1 Such deficiency would result in waste nitrogen circulating as ammonia and not being converted to glutamine. Immunosuppression and/or high-dose cytoreductive treatment might be responsible for the inactivation of glutamine synthetase.
We report here the case of a 52-year-old woman with locally advanced HER2 þ breast cancer and extensive breast and axillary involvement after preoperative chemotherapy with anthracyclines and taxanes, who was enrolled onto a phase II study of a novel high-dose regimen of trastuzumab/docetaxel/melphalan/carboplatin.
Her post transplant course was complicated with grade 4 colitis with multiorgan failure. After resolution of this toxicity, the patient remained obtunded. Her serum ammonia level was noticed to be high at 266 mg/dl, with normal serum GOT GPT, bilirubin and renal function parameters. No urease-producing bacteria were isolated in faeces. Amino-acid analyses (aspartic acid, glutamic acid, hydroxyproline, asparaginase, glycine, glutamine, taurine, histidine, citruline, threonine, alanine, arginine, proline, tyrosine, valine, methionine, cystine, isoleucine, leucine, phenylalanine, tryptophan, ornithine and lysine) were normal. Well-known iatrogenic causes of her hyperammonemia, such as valproic acid or asparaginase, were reasonably excluded. Lactulose enemas were unsuccessful, but ammonia-trapping treatment with intravenous and oral sodium benzoate resulted in gradual resolution of the neurological picture and normalization of the ammonia levels over the following 2 weeks. Following discharge, she received locoregional radiotherapy. She remains on maintenance triweekly trastuzumab treatment, free of disease and performance status 0 at last follow-up visit, 10 months after high-dose chemotherapy.
Few cases of post transplant IH have been previously described. [2] [3] [4] [5] [6] [7] Mitchell et al. 2 described nine cases, eight after intensive cytoreductive therapy and the ninth, 2 months after an allogeneic BMT. Only three of them survived. The longest series was reported by Davies and colleagues, including 12 patients, 10 of whom died from this complication, despite dialysis and ammonia-trapping therapy.
Idiopathic hyperammonemia is a highly lethal complication of BMT. Hyperammonemia needs to be ruled out in the presence of neurological deterioration of metabolic origin. Clinicians involved in the care of BMT patients need to be aware of this rare, albeit potentially fatal, diagnosis.
